4.6 Article

A perspective on Quality-by-Control (QbC) in pharmaceutical continuous manufacturing

Journal

COMPUTERS & CHEMICAL ENGINEERING
Volume 125, Issue -, Pages 216-231

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.compchemeng.2019.03.001

Keywords

Pharmaceutical continuous manufacturing; Process control; Quality-by-Design; Quality-by-Control; Process automation; Systems integration

Funding

  1. United States Food and Drug Administration [U01FD005535]
  2. National Science Foundation through the Engineering Research Center for Structured Organic Particulate Systems [EEC-0540855]

Ask authors/readers for more resources

The Quality-by-Design (QbD) guidance issued by the US Food and Drug Administration (FDA) has catalyzed the modernization of pharmaceutical manufacturing practices including the adoption of continuous manufacturing. Active process control was highlighted recently as a means to improve the QbD implementation. This advance has since been evolving into the concept of Quality-by-Control (QbC). In this study, the concept of QbC is discussed, including a definition of QbC, a review of the recent developments towards the QbC, and a perspective on the challenges of QbC implementation in continuous manufacturing. The QbC concept is demonstrated using a rotary tablet press, integrated into a pilot scale continuous direct compaction process. The results conclusively showed that active process control, based on product and process knowledge and advanced model-based techniques, including data reconciliation, model predictive control (MPC), and risk analysis, is indispensable to comprehensive QbC implementation, and ensures robustness and efficiency. (C) 2019 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available